Mostrar el registro sencillo del ítem
dc.contributor.author | García-Fernández, Alba![]() |
es_ES |
dc.contributor.author | Sancho, Mónica![]() |
es_ES |
dc.contributor.author | Garrido-García, Eva María![]() |
es_ES |
dc.contributor.author | Bisbal, Viviana![]() |
es_ES |
dc.contributor.author | Sancenón Galarza, Félix![]() |
es_ES |
dc.contributor.author | Martínez-Máñez, Ramón![]() |
es_ES |
dc.contributor.author | Orzáez, Mar![]() |
es_ES |
dc.date.accessioned | 2024-05-31T18:16:57Z | |
dc.date.available | 2024-05-31T18:16:57Z | |
dc.date.issued | 2023-11-10 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/204602 | |
dc.description.abstract | [EN] Acute lung injury (ALI) is a severe pulmonary disorder responsible for high percentage of mortality and morbidity in intensive care unit patients. Current treatments are ineffective, so the development of efficient and specific therapies is an unmet medical need. The activation of NLPR3 inflammasome during ALI produces the release of proinflammatory factors and pyroptosis, a proinflammatory form of cell death that contributes to lung damage spreading. Herein, it is demonstrated that modulating inflammasome activation through inhibition of ASC oligomerization by the recently described MM01 compound can be an alternative pharmacotherapy against ALI. Besides, the added efficacy of using a drug delivery nanosystem designed to target the inflamed lungs is determined. The MM01 drug is incorporated into mesoporous silica nanoparticles capped with a peptide (TNFR-MM01-MSNs) to target tumor necrosis factor receptor-1 (TNFR-1) to proinflammatory macrophages. The prepared nanoparticles can deliver the cargo in a controlled manner after the preferential uptake by proinflammatory macrophages and exhibit anti-inflammatory activity. Finally, the therapeutic effect of MM01 free or nanoparticulated to inhibit inflammatory response and lung injury is successfully demonstrated in lipopolysaccharide-mouse model of ALI. The results suggest the potential of pan-inflammasome inhibitors as candidates for ALI therapy and the use of nanoparticles for targeted lung delivery. | es_ES |
dc.description.sponsorship | This research was supported by Project Nos. PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2020-115048RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by European Regional Development Fund - A way of doing Europe. The authors also thank Generalitat Valenciana (PROMETEO Project CIPROM/2021/007 and PROMETEO 2019/065) for support. E.G. is grateful to the Spanish MIU and European Union-Next Generation EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would also like to thank Animal Facilities from Centro de Investigacion Principe Felipe for its support in the animal research and procedures, and I. Borred and J. Forteza from Instituto Valenciano de Patologia for its technical support in the histopathology analysis. The authors thank for the use of Biorender.com in the figures and graphical abstract. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Wiley-VCH | es_ES |
dc.relation.ispartof | Advanced Healthcare Materials (Online) | es_ES |
dc.rights | Reconocimiento - No comercial (by-nc) | es_ES |
dc.subject | MM01 | es_ES |
dc.subject | Acute lung injury | es_ES |
dc.subject | Mesoporous silica nanoparticles | es_ES |
dc.subject | Targeted-lung delivery | es_ES |
dc.subject.classification | QUIMICA ORGANICA | es_ES |
dc.subject.classification | QUIMICA INORGANICA | es_ES |
dc.title | Targeted Delivery of the Pan-Inflammasome Inhibitor MM01 as an Alternative Approach to Acute Lung Injury Therapy | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1002/adhm.202301577 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115048RB-I00/ES/EL INTERACTOMA DE MEMBRANA DE LAS PROTEINAS DE LA FAMILIA BCL-2 COMO DIANA ANTITUMORAL/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-126304OB-C41/ES/NUEVOS MATERIALES Y SONDAS PARA EL RECONOCIMIENTO, LIBERACION DE FARMACOS, NANOMOTORES Y COMUNICACION/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-128141OB-C22/ES/DESARROLLO DE NUEVOS MATERIALES INTELIGENTES Y SU APLICACION COMO SISTEMAS ANTIVIRALES, ANTIBIOFILM, ANTIENZIMATICOS Y ANTIMICROBIANOS PARA LA INDUSTRIA ALIMENTARIA./ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//PROMETEO%2F2019%2F065/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//CIPROM%2F2021%2F007/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MIU//UP2021-036/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials | es_ES |
dc.description.bibliographicCitation | García-Fernández, A.; Sancho, M.; Garrido-García, EM.; Bisbal, V.; Sancenón Galarza, F.; Martínez-Máñez, R.; Orzáez, M. (2023). Targeted Delivery of the Pan-Inflammasome Inhibitor MM01 as an Alternative Approach to Acute Lung Injury Therapy. Advanced Healthcare Materials (Online). 12(28). https://doi.org/10.1002/adhm.202301577 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1002/adhm.202301577 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 12 | es_ES |
dc.description.issue | 28 | es_ES |
dc.identifier.eissn | 2192-2659 | es_ES |
dc.identifier.pmid | 37515468 | es_ES |
dc.relation.pasarela | S\507397 | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Ministerio de Universidades | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |